FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

VACCINEX, INC.		 2. Issuer Name and Ticker or Trading Symbol

VACCINEX, INC. [ VCNX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE		 3. Date of Earliest Transaction (MM/DD/YYYY)

9/30/2019
(Street)

ROCHESTER, NY 14620
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

10/2/2019 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $10.00                   (1) 3/6/2020  Common Stock  4500    4500  D   
Stock Option (Right to Buy)  $14.90                   (1) 3/6/2023  Common Stock  7500    7500  D   
Stock Option (Right to Buy)  $13.60                   (1) 9/15/2027  Common Stock  6396    6396  D   
Stock Option (Right to Buy)  $5.26                   (1) 3/30/2029  Common Stock  2501    2501  D   
Stock Option (Right to Buy)  $7.78                  5/15/2020   (2) Common Stock  7718    7718  D   
Stock Option (Right to Buy)  $7.17  9/30/2019    A     1856      9/30/2019  9/27/2019  Common Stock  1856  $0.00 (3) 1856  D   

Explanation of Responses:
(1)  Exercisable in full as of the date of this report.
(2)  Except as otherwise provided in the award notice, this option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
(3)  Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable.

Remarks:
Due to a clerical error, this Form 4 filing was incorrectly made on behalf of the Company.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
VACCINEX, INC.
C/O VACCINEX, INC.
1895 MOUNT HOPE AVENUE
ROCHESTER, NY 14620 		X



Signatures
/s/ Scott E. Royer, Attorney-in-Fact for Gerald E. Van Strydonck 10/4/2019
**Signature of Reporting Person Date


Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Vaccinex Charts.
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Vaccinex Charts.
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....